Stereotaxis Reports 2020 Third Quarter Financial Results
“Stereotaxis is pleased to report revenue growth with the successful installation of the first Genesis RMN® and Model S Imaging Systems in both
“While hospitals remain negatively impacted by COVID-19, we have experienced a gradual return towards more normal capital planning. We received an additional order for a Genesis system from a US hospital that is establishing a new robotic electrophysiology program. Given the advanced status of multiple additional discussions, we are comfortable providing preliminary guidance for
“Stereotaxis’ advanced robotically-navigated magnetic ablation catheter is advancing on schedule with initial commercialization and initiation of a pivotal US trial expected in 2021. Meaningful progress continues on an additional wave of innovations within electrophysiology and beyond that are expected to drive transformational revenue growth. We expect to share details on this next wave of innovation towards the end of next year.”
Third Quarter 2020 Financial Results
Revenue for the third quarter of 2020 totaled
Gross margin in the quarter was
Cash Balance and Liquidity
At
Forward Looking Expectations
Conference Call and Webcast
About
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in
Company Contacts:
Chairman and Chief Executive Officer
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
STATEMENTS OF OPERATIONS | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenue: | |||||||||||||||
Systems | $ | 2,953,005 | $ | 1,696,964 | $ | 2,965,774 | $ | 1,755,015 | |||||||
Disposables, service and accessories | 5,504,048 | 6,258,252 | 16,099,915 | 19,515,125 | |||||||||||
Sublease | 246,530 | 246,532 | 739,590 | 739,593 | |||||||||||
Total revenue | 8,703,583 | 8,201,748 | 19,805,279 | 22,009,733 | |||||||||||
Cost of revenue: | |||||||||||||||
Systems | 3,031,440 | 665,463 | 3,253,976 | 722,828 | |||||||||||
Disposables, service and accessories | 747,285 | 919,599 | 2,068,085 | 2,928,718 | |||||||||||
Sublease | 246,530 | 246,531 | 739,590 | 739,592 | |||||||||||
Total cost of revenue | 4,025,255 | 1,831,593 | 6,061,651 | 4,391,138 | |||||||||||
Gross margin | 4,678,328 | 6,370,155 | 13,743,628 | 17,618,595 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 1,952,641 | 1,751,081 | 6,038,753 | 7,405,462 | |||||||||||
Sales and marketing | 2,822,680 | 3,120,632 | 8,279,853 | 9,666,975 | |||||||||||
General and administrative | 1,466,046 | 1,539,648 | 4,962,227 | 4,186,277 | |||||||||||
Total operating expenses | 6,241,367 | 6,411,361 | 19,280,833 | 21,258,714 | |||||||||||
Operating loss | (1,563,039 | ) | (41,206 | ) | (5,537,205 | ) | (3,640,119 | ) | |||||||
Interest income (expense) | (9,933 | ) | 84,954 | 71,596 | 133,329 | ||||||||||
Net income (loss) | $ | (1,572,972 | ) | $ | 43,748 | $ | (5,465,609 | ) | $ | (3,506,790 | ) | ||||
Cumulative dividend on convertible preferred stock | (343,101 | ) | (360,647 | ) | (1,028,950 | ) | (1,071,351 | ) | |||||||
Net loss attributable to common stockholders | $ | (1,916,073 | ) | $ | (316,899 | ) | $ | (6,494,559 | ) | $ | (4,578,141 | ) | |||
Net loss per share attributed to common stockholder: | |||||||||||||||
Basic | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.09 | ) | $ | (0.07 | ) | |||
Diluted | $ | (0.03 | ) | $ | (0.00 | ) | $ | (0.09 | ) | $ | (0.07 | ) | |||
Weighted average number of common shares and equivalents: | |||||||||||||||
Basic | 74,488,771 | 64,294,153 | 72,004,956 | 61,405,083 | |||||||||||
Diluted | 74,488,771 | 64,294,153 | 72,004,956 | 61,405,083 | |||||||||||
BALANCE SHEETS | |||||||
(Unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 43,595,829 | $ | 30,182,115 | |||
Compensating cash arrangement | 250,295 | - | |||||
Accounts receivable, net of allowance of |
5,409,722 | 5,329,577 | |||||
Inventories, net | 2,846,051 | 1,847,530 | |||||
Prepaid expenses and other current assets | 1,774,792 | 1,470,922 | |||||
Total current assets | 53,876,689 | 38,830,144 | |||||
Property and equipment, net | 234,858 | 250,443 | |||||
Operating lease right-of-use assets | 2,764,022 | 4,286,064 | |||||
Other assets | 256,669 | 218,103 | |||||
Total assets | $ | 57,132,238 | $ | 43,584,754 | |||
Liabilities and stockholders' equity | |||||||
Current liabilities: | |||||||
Short-term debt | $ | 457,244 | $ | - | |||
Accounts payable | 1,568,581 | 2,099,097 | |||||
Accrued liabilities | 2,956,130 | 2,721,104 | |||||
Deferred revenue | 6,189,796 | 5,092,455 | |||||
Current portion of operating lease liabilities | 2,275,436 | 2,248,189 | |||||
Total current liabilities | 13,447,187 | 12,160,845 | |||||
Long-term debt | 1,701,066 | - | |||||
Long-term deferred revenue | 569,475 | 554,258 | |||||
Operating lease liabilities | 540,536 | 2,089,537 | |||||
Other liabilities | 255,517 | 255,517 | |||||
Total liabilities | 16,513,781 | 15,060,157 | |||||
Series A - Convertible preferred stock: | |||||||
Convertible preferred stock, Series A, par value |
5,605,323 | 5,758,190 | |||||
Stockholders' equity: | |||||||
Convertible preferred stock, Series B, par value |
5,610 | 5,610 | |||||
Common stock, par value |
73,678 | 68,530 | |||||
Additional paid-in capital | 521,918,228 | 504,211,040 | |||||
(205,999 | ) | (205,999 | ) | ||||
Accumulated deficit | (486,778,383 | ) | (481,312,774 | ) | |||
Total stockholders' equity | 35,013,134 | 22,766,407 | |||||
Total liabilities and stockholders' equity | $ | 57,132,238 | $ | 43,584,754 | |||
Source: Stereotaxis, Inc.